United States · Bill · S
S. 4672 (116th)
TRANSPLANT Act of 2020
Introduced
23 September 2020
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S5835)
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020 This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies. Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells. In addition, the Government Accountability Office must examine various issues related to the national blood stem cell workforce.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 23 September 2020
Introduced in Senate (PDF)
Introduced in Senate · EN · 23 September 2020
Introduced in Senate
summary · EN · 23 September 2020
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/senate-bill/4672
- Open data entity: https://api.congress.gov/v3/bill/116/s/4672